Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|May 6, 2003
[New views on systemic mastocytosis]Andrzej Pluta, Krzysztof Gutkowski
Polskie Archiwum Medycyny Wewnetrznej|March 19, 2005
[Cranial fascitis--case report and literature review]Ewa Piekarz, Krzysztof Gutkowski, Andrzej Pluta, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|October 28, 2004
Severe sepsis in Poland--results of internet surveillance of 1043 casesAndrzej Kübler, Grazyna Durek, Agnieszka Zamirowska, et al.
Expert Review of Hematology|April 3, 2023
Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based reviewFrancesco Cinetto, Isabel Esteves Francisco, Klaus Fenchel, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|August 30, 2018
Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphomaEwa Wąsik-Szczepanek, Agnieszka Szymczyk, Dariusz Szczepanek, et al.
Hematological Oncology|June 8, 2012
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patientsNorbert Grzasko, Marek Hus, Andrzej Pluta, et al.
Annals of Hematology|June 24, 2011
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myelomaMarek Hus, Norbert Grzasko, Marta Szostek, et al.
Hemasphere|November 18, 2022
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial ResultsPaolo Ghia, Andrzej Pluta, Małgorzata Wach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaPaolo Ghia, Andrzej Pluta, Malgorzata Wach, et al.
Blood|October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsHervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.
Pageof 2